<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高解释</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1Vuepj4z_tesaaxkwjxbogotaabxd6u-nv BogotaAbxd6U-NVU8003KRCPQ8YLQC-＆UTM_SOURCE = CHROME＆FF = 20250312181054＆FC = 20230708114047＆V = 2.18.0.post9+E462414<description>心血管高额外版：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20250312181054&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> 2025年3月12日，星期三22:10:55 +0000</lastbuilddate><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>肥胖相关HFPEF的新型控制代谢加速器：Humain-HFPEF随机临床试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/40072462/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>结论和相关性：与肥胖相关的HFPEF患者中，用HU6治疗19周，可以进行统计学意义的体重减轻，而无需进行较大持续时间的较大试验。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：多余的身体脂肪在保留的射血分数（HFPEF）的心力衰竭的发病机理中起着关键作用（HFPEF）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估HU6在减轻体重的效率和安全性，改善肥胖相关HFPEF患者的氧气消耗量（VO2）和身体成分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，设置和参与者：探索性阶段，双盲，安慰剂控制的剂量升级研究，对肥胖HFPEF（Humain-HFPEF）受试者的安全性，药物动力学和药代动力学的安全性（Humain-HFPEF）试验是多中度临床疗法和肥胖的患者，是一项多中心疗法和肥胖的患者。七月至2024年10月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：HU6治疗19周，从每天150毫克开始，根据安全性和耐受性与安慰剂，可能会滴定至每天450毫克。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要终点是体重的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：66名参与者（平均[SD]年龄，64.5 [12]年； 38个女性[58％]；平均值[SD]体重110.9 [22.4] kg），56个hu6（VS安慰剂）的重量显着降低了群体差异。 2.96公斤; 95％CI，-4.50至-1.42 kg； .001）和内脏脂肪百分比（群体间差异-1.3％； 95％CI，-2.1至-0.5％; p = .003），没有明显的肌肉质量损失。或舒张功能在5名参与者（HU6组中有4个；安慰剂组中有1名）中注意到，其中1例死亡与治疗无关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：与肥胖相关的HFPEF患者中，用HU6治疗19周，可以进行统计学意义的体重减轻，而无需进行较大持续时间的较大试验。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov标识符：NCT05284617。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40072462</a> <a href=https://doi.org/10.1001/jamacardio.2025.0103>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40072462</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Ambarian Pandey</dc:creator><dc:creator>格雷戈里·刘易斯（Gregory D Lewis）</dc:creator><dc:creator> Barry a Borlaug</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator>安德鲁·J·索尔（Andrew J Sauer）</dc:creator><dc:creator> Sheldon Litwin</dc:creator><dc:creator>卡维塔·夏尔马（Kavita Sharma）</dc:creator><dc:creator> Diane K Jorkasky</dc:creator><dc:creator>伊丽莎白·塔卡（Elizabeth a Tarka）</dc:creator><dc:creator> Shaharyar M Khan</dc:creator><dc:creator> Dalane W Kitzman</dc:creator><dc:date> 2025-03-12</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>肥胖相关HFPEF的新型控制代谢加速器：Humain-HFPEF随机临床试验</dc:title><dc:identifier>PMID：40072462</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2025.0103</dc:identifier></item><item><title> FFR引导的经皮冠状动脉介入干预与冠状动脉搭桥术的糖尿病患者</title><link/>https://pubmed.ncbi.nlm.nih.gov/40072460/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>结论和相关性：在对成名的3个随机临床试验的亚组分析中，与FFR引导的PCI相比，CABG的相对益处在和患有糖尿病患者中相似。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：与冠状动脉搭桥术（CABG）相比，使用电流生成药物解脱支架（DES）的分数流量储备（FFR）引导的经皮冠状动脉干预（PCI）的糖尿病患者的结局是未知的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：根据糖尿病状况研究PCI与CABG的相对治疗效果，相对于3年的重大不良心脏和脑血管事件（MACCE），并评估语法得分的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，设置和参与者：这是对成名的预定亚组分析（分数储备与多发评估的血管造影）3试验，一项研究者在全球48名中心进行的研究者发起的随机临床试验，在全球48位中心进行了3个试验，与3次竞争者之间的coronary Coronary coronary cormonary canceronary canceronary casteronary canceronary casteronary casteronary canteronary。 2019年12月。数据分析于2023年8月进行。临床随访是在出院时，在随机化后的1个月，6个月，1年，2年和3年进行的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">干预：带有电流生成DES或CABG的FFR引导的PCI。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要终点是MACCE，定义为3年后全因死亡，心肌梗塞，中风或重复血运重建的综合。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在1500名患者中，平均（SD）年龄为65.1（8.4）年，女性（17.7％）是女性的名声3次。 FFR引导的PCI与两名糖尿病患者的CABG相比（危险比[HR]，1.44; 95％CI，0.91-2.28; p = .12）和没有糖尿病的患者（HR，1.50; 95％CI，1.08-2.07; P = .02），没有显着差异（p ins for Priens for Priens for Prients Interaction in Interaction）。 PCI和CABG之间的MACCE，而无论糖尿病状况如何，PCI的中等至高语法评分（≥23）的患者的MACCE风险高于CABG。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在对成名的3个随机临床试验的亚组分析中，与FFR引导的PCI相比，CABG的相对益处在和患有糖尿病患者中相似。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">试验注册：ClinicalTrials.gov标识符：NCT02100722。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40072460/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40072460</a> <a href=https://doi.org/10.1001/jamacardio.2025.0095>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40072460</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>库尼基高桥</dc:creator><dc:creator>Hisao Otsuki</dc:creator><dc:creator>弗雷德里克·齐默尔曼（Frederik M Zimmermann）</dc:creator><dc:creator>维多利亚y丁</dc:creator><dc:creator>托马斯·恩格斯特斯特斯特</dc:creator><dc:creator>汉斯·古斯塔夫·霍斯特·蒂格德</dc:creator><dc:creator>Branko Beleslin</dc:creator><dc:creator> Svetozar Putnik</dc:creator><dc:creator>卢克·塔普（Luke Tapp）</dc:creator><dc:creator>托马斯·巴克（Thomas Barker）</dc:creator><dc:creator>西蒙·雷德伍德</dc:creator><dc:creator>克里斯托弗·杨</dc:creator><dc:creator>G Jan-Willem Bech</dc:creator><dc:creator> Gerard JF Hoohenkerk</dc:creator><dc:creator>伯纳德·德·布鲁恩（Bernard de Bruyne）</dc:creator><dc:creator> Nico HJ Pijls</dc:creator><dc:creator>威廉·F·费顿</dc:creator><dc:creator>名望3审判调查员</dc:creator><dc:date>2025-03-12</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>FFR引导的经皮冠状动脉介入干预与冠状动脉搭桥术的糖尿病患者</dc:title><dc:identifier>PMID：40072460</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2025.0095</dc:identifier></item><item><title>美国黑人和白人个人中的粮食不安全和事件心血管疾病，2000-2020</title><link/> https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>结论和相关性：在Cardia研究的参与者中，即使对社会经济因素进行调整，粮食不安全感也与事件CVD有关，这表明粮食不安全感可能是临床评估的重要社会剥夺度量，以降低粮食的风险。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：粮食不安全与普遍的心血管疾病（CVD）有关，但研究仅限于横断面数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：研究粮食不安全是否与事件CVD相关，并确定这种关联是随着性，教育还是种族的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计，设置和参与者：这项前瞻性队列研究是在美国成年人中进行的，没有预先存在的CVD参与Cardia（年轻人的冠状动脉风险开发）研究于2000年至2020年8月31日。数据分析是从2022年12月至2024年4月进行的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：在2000-2001期间评估的粮食不安全，定义为在家庭食物种类和/或粮食数量中的限制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和措施：主要结果是CVD事件，包括致命和非致命性心脏病，心力衰竭，中风，短暂性缺血性发作或周围动脉疾病，每年鉴定为每年至2020年8月31日。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在3616名成年人中，平均年龄为40.1（3.6）年，有2027名参与者（56％）为3616名参与者。 （3.4）在此期间发生了255次CVD事件：在研究期间调整了年龄，性别和野外中心后，食品不确定性参与者的57个事件（11％）和食品安全参与者的198个事件（6％）。我，1.08-2.01）之后进一步调整教育的社会经济因素，婚姻状况和通常的医疗来源。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在Cardia研究的参与者中，即使对社会经济因素进行调整，粮食不安全感也与事件CVD有关，这表明粮食不安全感可能是临床评估的重要社会剥夺度量，以降低粮食的风险。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40072427</a> <a href=https://doi.org/10.1001/jamacardio.2025.0109>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40072427</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>珍妮·贾（Jenny Jia）</dc:creator><dc:creator>梅赛德斯·卡纳森（Mercedes R Carnethon）</dc:creator><dc:creator>曼迪·黄</dc:creator><dc:creator>Cora E Lewis</dc:creator><dc:creator> Pamela J Schreiner</dc:creator><dc:creator> Namratha R Kandula</dc:creator><dc:date> 2025-03-12</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>美国黑人和白人个人中的粮食不安全和事件心血管疾病，2000-2020</dc:title><dc:identifier> PMID：40072427</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2025.0109</dc:identifier></item><item><title>运动引起的妇女患有冠状动脉疾病的老年妇女</title><link/>https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40072426</a> <a href=https://doi.org/10.1001/jamacardio.2025.0115>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40072426</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>听起来很棒的m&#39;rabet</dc:creator><dc:creator>让 - 克里斯托弗·艾希尔（Jean-Christophe Eicher）</dc:creator><dc:creator>查尔斯·瓜纳西亚</dc:creator><dc:date>2025-03-12</dc:date><dc:source> JAMA心脏病学</dc:source><dc:title>运动引起的妇女患有冠状动脉疾病的老年妇女</dc:title><dc:identifier>PMID：40072426</dc:identifier><dc:identifier> doi：10.1001/jamacardio.2025.0115</dc:identifier></item><item><title> PCSK9通过防止SNX17介导的LDLR回收来促进LDLR降解</title><link/>https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>结论：PCSK9通过防止SNX17介导的LDLR回收来促进LDLR降解。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年3月12日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：低密度脂蛋白（LDL）主要通过LDLR（LDL受体）介导的内吞作用，在酸性内体中，LDLR从LDL中释放出来，并将其回收回到细胞表面，而LDL则将LDL留在ldl中，而LDL则在内体中脱落了9个condracins croptimin croplies croplies croplies croplies contries contries contries contries contriping。使用LDLR并将内部化为内体，类似于LDL。酸性内体的LDLR无法与PCSK脱离，并且在PCSK9抑制剂中脱落了两个蛋白质。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用体内和体内方法来研究PCSK9介导<i>的</i>LDLR降解<i>的</i>分子和细胞机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：酸性pH会引起LDLR外细胞域的会议变化，并通过细胞内域促进其与SNX17的相互作用（分类Nexin 17 <i>）。击倒SNX17</i><i>废除</i>PCSK9 <i>LDLR</i>降解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：PCSK9通过防止SNX17<i>介</i>导的LDLR回收来促进LDLR降解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40071387</a> <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072336>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40071387</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>扬阳关</dc:creator><dc:creator>小米刘</dc:creator><dc:creator>Zetian Yang</dc:creator><dc:creator> Xinyu Zhu</dc:creator><dc:creator> Min Liu</dc:creator><dc:creator> Mingkun du</dc:creator><dc:creator>小pan</dc:creator><dc:creator>杨王</dc:creator><dc:date>2025-03-12</dc:date><dc:source>循环</dc:source><dc:title>PCSK9通过防止SNX17介导的LDLR回收来促进LDLR降解</dc:title><dc:identifier>PMID：40071387</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.072336</dc:identifier></item><item><title>髓样脂肪酸代谢激活相邻的造血干细胞，以保留的射血分数促进心力衰竭</title><link/>https://pubmed.ncbi.nlm.nih.gov/40071347/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>结论：这些发现确定了心脏代谢HFPEF的重要新干细胞特征，并支持髓样疾病疾病疾病脂肪酸代谢在促进全身感染和心脏舒张功能障碍中的作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年3月12日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尽管弹出率（HFPEF）的心力衰竭的发病率很高，但HFPEF综合征仍然有限。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：比较患者样品和动物模型，我们定义了HFPEF原位和流式细胞仪和单细胞RNA测序的先天免疫响应。光谱法和碳标记。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们报告的证据表明，在高脂饮食的鼠模式下，具有较高的血液造血性干细胞的患者是<i>在</i>外周血造血细胞中的升高被钠葡萄糖部分抑制共转运蛋白-2抑制剂，并用巨噬细胞线粒体中的脂肪酸代谢升高来解释，进而将<i>VCAM1</i>启动子重塑以增强其表达。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些发现确定了心脏代谢HFPEF的重要新干细胞特征，并支持髓样疾病疾病疾病脂肪酸代谢在促进全身感染和心脏舒张功能障碍中的作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40071347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40071347</a> <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070248>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40071347</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Mallory Filipp</dc:creator><dc:creator> Zhi-Dong GE</dc:creator><dc:creator>马修·德伯格（Matthew Deberge）</dc:creator><dc:creator>康纳·兰兹（Connor Lantz）</dc:creator><dc:creator>克里斯托弗·格林顿</dc:creator><dc:creator>彭高</dc:creator><dc:creator>Sasha Smolgovsky</dc:creator><dc:creator> Jingbo Dai</dc:creator><dc:creator>你杨Zhao</dc:creator><dc:creator> Laurent Yvan-Charvet</dc:creator><dc:creator>皮拉尔·阿尔卡德（Pilar Alcaide）</dc:creator><dc:creator>塞缪尔·温伯格</dc:creator><dc:creator>Gabriele G Schiattarella</dc:creator><dc:creator>约瑟夫·阿山</dc:creator><dc:creator>Matthew J Feinstein</dc:creator><dc:creator> Sanjiv J Shah</dc:creator><dc:creator>爱德华·B·索普（Edward B Thorp）</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>循环</dc:source><dc:title>髓样脂肪酸代谢激活相邻的造血干细胞，以保留的射血分数促进心力衰竭</dc:title><dc:identifier>PMID：40071347</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.070248</dc:identifier></item><item><title>内皮5-羟色胺受体1b充当驱动动脉粥样硬化的机械传感器</title><link/>https://pubmed.ncbi.nlm.nih.gov/40071330/？ 8114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>结论：综上所述，这些结果发现内皮5-HT（1B）是流动障碍的机理，并有助于动脉粥样硬化。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res。2025年3月12日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：动脉粥样硬化的特征是脂肪和纤维化斑块的积累，这些斑块优先在沿着动脉树的弯曲和分支上发展，而这些动脉树暴露于受影响的流动中。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用IBIDI系统进行骨动脉粥样<sub>硬化</sub>实验的局部颈动脉结扎<sub>模型</sub>。 RNA<i>测序</i>分析，免疫<sup><i>荧光</i></sup>分析和分子生物学技术用于探索5-HT <sub>1B</sub>在机械转导和内皮激活中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：数据表明，人类内皮细胞表达高水平的5-HT <sub>1b</sub> ，这是一种脑部和啮齿动物的动脉粥样硬化区域中，<sub>这是一种血清素的5-HT 1B</sub> <sub>。</sub> <sub>hibits</sub>扰乱了流动引起的在雄性和女性<i>apoE</i> <sup><i>- / -</i></sup>小鼠中，我们<sub>的</sub>内皮炎症和动脉<sub>粥</sub>样硬化。 ation和单核细胞浸润5-HT <sub>1B</sub>的桶通过抑制YAP抑制内皮激活和动脉粥样硬化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：综上所述，这些结果发现内皮5-HT <sub>1B</sub>充当流动障碍<sub>的</sub>机理，并有助于动脉粥样硬化。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40071330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40071330</a> <a href=https://doi.org/10.1161/CIRCRESAHA.124.325453>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40071330</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Minchun Jiang</dc:creator><dc:creator>华努丁</dc:creator><dc:creator>Yuhong Huang</dc:creator><dc:creator> Chi Wai Lau</dc:creator><dc:creator> Ying Guo</dc:creator><dc:creator> Jianfang Luo</dc:creator><dc:creator> Yu-Tsung Shih</dc:creator><dc:creator> Yin Xia</dc:creator><dc:creator> Xiaoqiang Yao</dc:creator><dc:creator> Jeng-Jiann Chiu</dc:creator><dc:creator>李王</dc:creator><dc:creator>Shu Chien</dc:creator><dc:creator> Yu Huang</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>循环研究</dc:source><dc:title>内皮5-羟色胺受体1b充当驱动动脉粥样硬化的机械传感器</dc:title><dc:identifier>PMID：40071330</dc:identifier><dc:identifier> doi：10.1161/circresaha.124.325453</dc:identifier></item><item><title> NRF2/β3-肾上腺素受体轴驱动持续的抗氧化剂和代谢重新布线，通过五旬节 - 磷酸途径减轻心脏应激</title><link/>https://pubmed.ncbi.nlm.nih.gov/40071326/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>结论：心脏心肌中观察到的心脏β3AR中等表达，通过激活戊糖磷酸途径和NRF2途径通过KEAP1的S-硝化作用，从而通过KKEAP的S-硝化来发挥代谢和抗氧化作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。2025年3月12日。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：β3-肾上腺素能受体（ARS）在否认的心脏和β3AR激动剂的培养基对比中被上调。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：从具有现代心脏的<i>ADRB3</i>转基因（β3AR-TG）的小鼠中解剖功能，转录和代谢作用，心脏和孤立的心室心肌细胞，并通过超声心动术，rna序列和信号分析，对横向主动脉收缩进行了横向主动脉收缩。橄榄途径在β3AR-TG中进一步研究了新生大鼠心室心肌细胞的体内，腺病毒感染以表达β3AR并遭受这些结果，通过对人类心脏失败患者的单核RNA的分析来完成这些结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与野生型窝窝相比，β3AR-TG小鼠免受透射收缩后的肥大，并且保留了表达β3AR的心脏的收缩功能。 β3AR-TG，一种替代方案葡萄糖利用的途径与五旬节 - 磷酸盐途径的NADPH产生和限速酶的转录水平增加，而无需加油，而六糖胺代谢的含量增加了，从而确保了增加的谷胱甘肽的含量降低，并降低了谷胱甘肽的氧化物氧气氧气氧化物的氧化物氧化物的氧气降低。跨股票收缩后的G小鼠Unbiased transcription and pathway analysis identified NRF2 (NFE2L2) as an upstream transcription factor that was functionally verified in vivo and in β3AR-expressing cardiac myocytes, where its translocation and nuclear activity were dependent on β3AR activation of nitric oxide synthase and nitric oxide production through S-nitrosation of the NRF2-negative regulator Keap1。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：心脏心肌中观察到的心脏β3AR中等表达，通过激活戊糖磷酸途径和NRF2途径通过KEAP1的S-硝化作用，从而通过KKEAP的S-硝化来发挥代谢和抗氧化作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40071326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40071326</a> <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067876>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40071326</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Lauriane YM Michel</dc:creator><dc:creator> Hrag Esfahani</dc:creator><dc:creator> Delphine de Mulder</dc:creator><dc:creator> Roxane Verdoy</dc:creator><dc:creator> JérômeAmbroise</dc:creator><dc:creator> VéroniqueRoelants</dc:creator><dc:creator>伯特兰·布沙德（Bertrand Bouchard）</dc:creator><dc:creator>纳塔莉·法比安（Nathalie Fabian）</dc:creator><dc:creator> JérômeSavary</dc:creator><dc:creator>约瑟夫·迪瓦夫</dc:creator><dc:creator>托马斯·杜蒙特</dc:creator><dc:creator>Caroline Bouzin</dc:creator><dc:creator> Vincent Haufroid</dc:creator><dc:creator> Joost JFP Luiken</dc:creator><dc:creator>米兰达·纳本（Miranda Nabben）</dc:creator><dc:creator>迈克尔·辛格尔顿</dc:creator><dc:creator>卢克·伯特兰（Luc Bertrand）</dc:creator><dc:creator> Matthieu Ruiz</dc:creator><dc:creator>克里斯汀·德·罗西尔（Christine des Rosiers）</dc:creator><dc:creator>让·卢克·巴利加德（Jean-Luc Balligand）</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>循环</dc:source><dc:title>NRF2/β3-肾上腺素受体轴驱动持续的抗氧化剂和代谢重新布线，通过五旬节 - 磷酸途径减轻心脏应激</dc:title><dc:identifier>PMID：40071326</dc:identifier><dc:identifier> doi：10.1161/CirculationAha.124.067876</dc:identifier></item><item><title>极性引导的不平坦有丝分裂控制增殖的植物根细胞中的黄铜固醇活性</title><link/>https://pubmed.ncbi.nlm.nih.gov/40068682/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description>培养基是植物器官生长的积极调节剂，但是它们在增殖时的功能尚不清楚，通过将单细胞RNA测序与拟南芥根的长期活细胞成像整合在一起，我们揭示了在整个细胞分裂过程中均降低了伊斯兰教徒的培训。母亲的极性... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 3月6日， <b>Cell</b> 。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">培养基是植物器官生长的积极调节剂，但是它们在增殖时的功能尚不清楚，通过将单细胞RNA测序与拟南芥根的长期活细胞成像整合在一起，我们揭示了在整个细胞分裂过程中均降低了伊斯兰教徒的培训。母细胞的极性导致一个女儿细胞具有增强的黄铜固醇信号传导，而另一个人的Brassinosteroid osynthesis（在G1期间，这些不同的子细胞状态的共存）则可以避免使用信号的序列，从而促进了brassin sermention complient inserion complient complient inserion complient sivise nouts sive complient siviserion complient sivisers complient inserion complient inserion comply seviention。生长。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40068682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40068682</a> <a href=https://doi.org/10.1016/j.cell.2025.02.011>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40068682</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> NemanjaVukašinović</dc:creator><dc:creator> che-wei hsu</dc:creator><dc:creator> Marco Marconi</dc:creator><dc:creator> Shaopeng Li</dc:creator><dc:creator>克里斯托弗·扎卡里（Christopher Zachary）</dc:creator><dc:creator>瑞秋·沙汉（Rachel Shahan）</dc:creator><dc:creator> Pablo Szekley</dc:creator><dc:creator> ZIV审查</dc:creator><dc:creator>伊莎贝尔·范霍特（Isabelle Vanhoutte）</dc:creator><dc:creator> Qian MA</dc:creator><dc:creator> Lucrezia Pinto</dc:creator><dc:creator>帕维尔·克鲁帕</dc:creator><dc:creator>内森德语</dc:creator><dc:creator>Jingyuan Zhang</dc:creator><dc:creator>克莱尔·西蒙·韦佐（Claire Simon-Vezo）</dc:creator><dc:creator>杰西卡·佩雷斯·桑乔（Jessica Perez-Sancho）</dc:creator><dc:creator> Pepe Cana Quijada</dc:creator><dc:creator> Qianzi Zhou</dc:creator><dc:creator>劳拉·李（Laura R Lee）</dc:creator><dc:creator> Jianghua Cai</dc:creator><dc:creator> Emmanuelle M Bayer</dc:creator><dc:creator> MatyášFendrych</dc:creator><dc:creator> Elisabeth Truernit</dc:creator><dc:creator> Yu Zhou</dc:creator><dc:creator> Sigal Savaldi-Goldstein</dc:creator><dc:creator> Krzysztof Wabnik</dc:creator><dc:creator> Trevor M Nolan</dc:creator><dc:creator> Eugenia Russinova</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>细胞</dc:source><dc:title>极性引导的不平坦有丝分裂控制增殖的植物根细胞中的黄铜固醇活性</dc:title><dc:identifier>PMID：40068682</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.02.011</dc:identifier></item><item><title>婴儿肠道共生双歧杆菌中的基因组规模资源揭示了定殖和宿主 - 微生物相互作用的遗传决定剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/40068681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>双歧杆菌在婴儿期间代表人类肠道微生物的主要构成，影响营养，免疫发展和对感染的抗性，尽管对生物疗法的理解，我们对生物疗法的理解，对宿主互动的理解，并创建了Bififidobactia的范围。双歧杆菌的亚元。首先，我们... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> 3月7日：0092-8674（25）00195-3：10.1016 <b>/</b> j.cell.2025.02.010</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">双歧杆菌在婴儿期间代表人类肠道微生物的主要构成，影响营养，免疫发展和对感染的抗性，尽管对生物疗法的理解，我们对生物疗法的理解，对宿主互动的理解，并创建了Bififidobactia的范围。双歧杆菌的亚元。首先，我们生成了一个随机的条形码转座插入池，并在无多种饮食的无菌小鼠和鸡的定殖过程中确定了适应性，并响应数百个体外扰动，以启用机械投资。免疫调节分子以增加利益。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40068681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40068681</a> <a href=https://doi.org/10.1016/j.cell.2025.02.010>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40068681</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator>安东尼·l颤抖</dc:creator><dc:creator>jiawei sun</dc:creator><dc:creator>丽贝卡·卡尔弗（Rebecca Culver）</dc:creator><dc:creator> Arvie Violette</dc:creator><dc:creator> Char Wynter</dc:creator><dc:creator> Marta Nieckarz</dc:creator><dc:creator> Samara Paula Mattiello</dc:creator><dc:creator> Prabhjot Kaur Sekhon</dc:creator><dc:creator> Francesca Bottacini</dc:creator><dc:creator>丽莎·弗里斯（Lisa Friess）</dc:creator><dc:creator>汉斯·卡尔森</dc:creator><dc:creator>Daniel Pgh Wong</dc:creator><dc:creator>史蒂文·希金博特姆（Steven Higginbottom）</dc:creator><dc:creator> Meredith Weglarz</dc:creator><dc:creator> Weigao Wang</dc:creator><dc:creator>本杰明·纳普（Benjamin D Knapp）</dc:creator><dc:creator>艾玛·吉布森（Emma Guiberson）</dc:creator><dc:creator>胡安·桑切斯</dc:creator><dc:creator>Po-hsun黄</dc:creator><dc:creator>保罗是加西亚</dc:creator><dc:creator>Cullen R Buie</dc:creator><dc:creator>本杰明·H好</dc:creator><dc:creator>Brian DeFelice</dc:creator><dc:creator>费利佩·卡瓦（Felipe Cava）</dc:creator><dc:creator>欢乐吓人</dc:creator><dc:creator>贾斯汀·索南堡（Justin L Sonnenburg）</dc:creator><dc:creator>杜威·范·辛德登（Douwe Van Sinderen）</dc:creator><dc:creator>亚当·M·德意志布尔（Adam M Deutschbauer）</dc:creator><dc:creator> Kerwyn Casey Huang</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>细胞</dc:source><dc:title>婴儿肠道共生双歧杆菌中的基因组规模资源揭示了定殖和宿主 - 微生物相互作用的遗传决定剂</dc:title><dc:identifier>PMID：40068681</dc:identifier><dc:identifier> doi：10.1016/j.cell.2025.02.010</dc:identifier></item><item><title>通过重组末端加入人类线粒体，工程mtDNA删除</title><link/>https://pubmed.ncbi.nlm.nih.gov/40068680/？ 08114047＆ff = 20250312181054＆v = 2.18.0.post9+e462414<description> Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to mitochondrial myopathies remains challenging. Here, we engineered mtDNA deletions in human cells by co-expressing end-joining (EJ) machinery and targeted endonucleases. Using mitochondrial EJ (mito-EJ) and mito-ScaI, we generated a panel of clonal cell lines... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2025 Mar 5:S0092-8674(25)00194-1. doi: 10.1016/j.cell.2025.02.009. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to mitochondrial myopathies remains challenging. Here, we engineered mtDNA deletions in human cells by co-expressing end-joining (EJ) machinery and targeted endonucleases. Using mitochondrial EJ (mito-EJ) and mito-ScaI, we generated a panel of clonal cell lines harboring a ∼3.5 kb mtDNA deletion across the full spectrum of heteroplasmy. Investigating these cells revealed a critical threshold of ∼75% deleted genomes, beyond which oxidative phosphorylation (OXPHOS) protein depletion, metabolic disruption, and impaired growth in galactose-containing media were observed. Single-cell multiomic profiling identified two distinct nuclear gene deregulation responses: one triggered at the deletion threshold and another progressively responding to heteroplasmy. Ultimately, we show that our method enables the modeling of disease-associated mtDNA deletions across cell types and could inform the development of targeted therapies.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40068680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40068680</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2025.02.009>10.1016/j.cell.2025.02.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40068680</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Yi Fu</dc:creator><dc:creator> Max Land</dc:creator><dc:creator> Tamar Kavlashvili</dc:creator><dc:creator> Ruobing Cui</dc:creator><dc:creator> Minsoo Kim</dc:creator><dc:creator> Emily DeBitetto</dc:creator><dc:creator> Toby Lieber</dc:creator><dc:creator> Keun Woo Ryu</dc:creator><dc:creator> Elim Choi</dc:creator><dc:creator> Ignas Masilionis</dc:creator><dc:creator> Rahul Saha</dc:creator><dc:creator> Meril Takizawa</dc:creator><dc:creator> Daphne Baker</dc:creator><dc:creator> Marco Tigano</dc:creator><dc:creator> Caleb A Lareau</dc:creator><dc:creator> Ed Reznik</dc:creator><dc:creator> Roshan Sharma</dc:creator><dc:creator> Ronan Chaligne</dc:creator><dc:creator> Craig B Thompson</dc:creator><dc:creator> Dana Pe&#39;er</dc:creator><dc:creator> Agnel Sfeir</dc:creator><dc:date> 2025-03-11</dc:date><dc:source> Cell</dc:source><dc:title> Engineering mtDNA deletions by reconstituting end joining in human mitochondria</dc:title><dc:identifier> pmid:40068680</dc:identifier><dc:identifier> doi:10.1016/j.cell.2025.02.009</dc:identifier></item><item><title> Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Among at-risk patients undergoing CAG or PCI, the incidence of CA-AKI was lower in patients receiving delayed compared with sham RIPC. These results should be confirmed in larger trials to investigate whether reductions in CA-AKI with delayed RIPC lead to important clinical benefits. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf135. doi: 10.1093/eurheartj/ehaf135. Online ahead of print.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Remote ischaemic pre-conditioning (RIPC) delivered shortly prior to an angiographic procedure may reduce contrast-associated acute kidney injury (CA-AKI). Whether a longer interval between RIPC and contrast administration also reduces CA-AKI and post-procedural complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) is unknown. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This was a multicentre, randomized trial of patients at risk of CA-AKI undergoing elective CAG or PCI comparing delayed RIPC (four cycles of 5 min inflations on one upper arm 24 h before the procedure) with sham RIPC. The primary endpoint was the incidence of AKI, defined according to the Kidney Disease Improving Global Outcomes criteria. Secondary endpoints included renal replacement therapy during hospitalization, changes in urinary biomarkers of kidney injury, and occurrence of non-fatal myocardial infarction, stroke, re-hospitalization, and all-cause mortality by day 90. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Altogether, 501 patients (age, 74 [66, 78] years) were randomly assigned to delayed (n = 250) or sham (n = 251) RIPC, of which 467 (93.2%) completed outcome assessments at day 90. The incidence of CA-AKI was 7.6% with sham and 3.2% with delayed RIPC (odds ratio 0.4, 95% confidence interval 0.17-0.94; P = .03). The trial was not adequately powered to show effects on secondary outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Among at-risk patients undergoing CAG or PCI, the incidence of CA-AKI was lower in patients receiving delayed compared with sham RIPC. These results should be confirmed in larger trials to investigate whether reductions in CA-AKI with delayed RIPC lead to important clinical benefits.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067773</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf135>10.1093/eurheartj/ehaf135</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067773</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Ping Jia</dc:creator><dc:creator> Gang Zhao</dc:creator><dc:creator> Yuli Huang</dc:creator><dc:creator> Zhouping Zou</dc:creator><dc:creator> Qi Zeng</dc:creator><dc:creator> Weize Chen</dc:creator><dc:creator> Ting Ren</dc:creator><dc:creator> Yang Li</dc:creator><dc:creator> Xiaoyan Wang</dc:creator><dc:creator> Tingting Kang</dc:creator><dc:creator> Zhihe Liu</dc:creator><dc:creator> Mengqing Ma</dc:creator><dc:creator> Jiwei Yu</dc:creator><dc:creator> Qiong Wu</dc:creator><dc:creator> Bing Deng</dc:creator><dc:creator> Xiaoxiang Yan</dc:creator><dc:creator> Xin Wan</dc:creator><dc:creator> Xin Chen</dc:creator><dc:creator> Changchun Cao</dc:creator><dc:creator> Junbo Ge</dc:creator><dc:creator> Xiaoqiang Ding</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial</dc:title><dc:identifier> pmid:40067773</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf135</dc:identifier></item><item><title> Epicardial adipose tissue and malignant ventricular arrhythmias in phospholamban p.(Arg14del) variant carriers</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf118. doi: 10.1093/eurheartj/ehaf118. Online ahead of print.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067768</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf118>10.1093/eurheartj/ehaf118</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067768</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Belend Mahmoud</dc:creator><dc:creator> Moniek GPJ Cox</dc:creator><dc:creator> Remco de Brouwer</dc:creator><dc:creator> Myrthe YC van der Heide</dc:creator><dc:creator> Thomas M Gorter</dc:creator><dc:creator> Laura MG Meems</dc:creator><dc:creator> Arthur AM Wilde</dc:creator><dc:creator> Dirk J van Veldhuisen</dc:creator><dc:creator> Rudolf A de Boer</dc:creator><dc:creator> B Daan Westenbrink</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Epicardial adipose tissue and malignant ventricular arrhythmias in phospholamban p.(Arg14del) variant carriers</dc:title><dc:identifier> pmid:40067768</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf118</dc:identifier></item><item><title> Cardiovascular safety of assisted reproductive technologies: what have we learned and what remains unknown?</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf108. doi: 10.1093/eurheartj/ehaf108. Online ahead of print.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067679</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf108>10.1093/eurheartj/ehaf108</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067679</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Zhenjiao Liang</dc:creator><dc:creator> Dongna Wang</dc:creator><dc:creator> Xiaoping Wang</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Cardiovascular safety of assisted reproductive technologies: what have we learned and what remains unknown?</dc:title><dc:identifier> pmid:40067679</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf108</dc:identifier></item><item><title> Cardiovascular safety of assisted reproductive technologies: what is next?</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf088. doi: 10.1093/eurheartj/ehaf088. Online ahead of print.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067673</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf088>10.1093/eurheartj/ehaf088</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067673</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Carlo Andrea Pivato</dc:creator><dc:creator> Giulio Stefanini</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Cardiovascular safety of assisted reproductive technologies: what is next?</dc:title><dc:identifier> pmid:40067673</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf088</dc:identifier></item><item><title> Oral health benefits and safety of xylitol and potential cardiovascular risk: questioning the validity of the model of Witkowski et al</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf058. doi: 10.1093/eurheartj/ehaf058. Online ahead of print.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067657</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf058>10.1093/eurheartj/ehaf058</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067657</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Gregory C Valentine</dc:creator><dc:creator> Eva Söderling</dc:creator><dc:creator> Peter Milgrom</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Oral health benefits and safety of xylitol and potential cardiovascular risk: questioning the validity of the model of Witkowski et al</dc:title><dc:identifier> pmid:40067657</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf058</dc:identifier></item><item><title> Xylitol and cardiovascular risks</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2025 Mar 11:ehaf059. doi: 10.1093/eurheartj/ehaf059. Online ahead of print.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067656</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehaf059>10.1093/eurheartj/ehaf059</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067656</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Marco Witkowski</dc:creator><dc:creator> Stanley L Hazen</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>欧洲心脏期刊</dc:source><dc:title>Xylitol and cardiovascular risks</dc:title><dc:identifier> pmid:40067656</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehaf059</dc:identifier></item><item><title> Highlights From the Circulation Family of Journals</title><link/> https://pubmed.ncbi.nlm.nih.gov/40067098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2024 Oct 29;150(18):1469-1474. doi: 10.1161/CIRCULATIONAHA.124.072348. Epub 2024 Oct 28.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40067098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40067098</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072348>10.1161/CIRCULATIONAHA.124.072348</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40067098</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:date> 2025-03-11</dc:date><dc:source>循环</dc:source><dc:title>Highlights From the Circulation Family of Journals</dc:title><dc:identifier> pmid:40067098</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.124.072348</dc:identifier></item><item><title>周围血管疾病的性别差异：美国心脏协会的科学陈述</title><link/>https://pubmed.ncbi.nlm.nih.gov/40066579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>危险因素，诊断，治疗和心血管疾病患者的结局已得到很好的描述；但是，大部分文献都集中在女性的心脏病中。一群疾病... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">危险因素，诊断，治疗和心血管疾病患者的结局已得到很好的描述；但是，大部分文献都集中在女性的心脏病中。这项科学陈述的目的是报告外周血管疾病中基于性别的差异和差异的当前状态，并提供研究优先级，以实现周围血管疾病的妇女的健康公平。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40066579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40066579</a> <a href=https://doi.org/10.1161/CIR.0000000000001310>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40066579</guid><pubDate> Tue, 11 Mar 2025 06:00:00 -0400</pubDate><dc:creator>以斯帖·什·金（Esther Sh Kim）</dc:creator><dc:creator>希普拉·艾莉亚（Shipra Arya）</dc:creator><dc:creator> Yolanda Bryce</dc:creator><dc:creator>希瑟·L·戈尼克（Heather L Gornik）</dc:creator><dc:creator>钱德勒很长</dc:creator><dc:creator>玛丽·麦克德莫特（Mary M McDermott）</dc:creator><dc:creator>艾米·韦斯特·波拉克（Amy West Pollak）</dc:creator><dc:creator> Vincent Lopez Rowe</dc:creator><dc:creator>亚历山大·E·沙利文（Alexander E Sullivan）</dc:creator><dc:creator>玛丽·惠普</dc:creator><dc:creator>美国心血管疾病和临床心脏病学委员会的心脏疾病委员会；</dc:creator><dc:date> 2025-03-11</dc:date><dc:source>循环</dc:source><dc:title>周围血管疾病的性别差异：美国心脏协会的科学陈述</dc:title><dc:identifier>PMID：40066579</dc:identifier><dc:identifier> doi：10.1161/cir.0000000001310</dc:identifier></item><item><title>纠正：女性大师耐力运动员的冠状动脉粥样硬化患病率</title><link/>https://pubmed.ncbi.nlm.nih.gov/40063726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40063726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40063726</a> <a href=https://doi.org/10.1161/CIR.0000000000001320>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40063726</guid><pubDate> Mon, 10 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Efstathios Papatheodorou</dc:creator><dc:creator> Vincent L Aengevaeren</dc:creator><dc:creator> Thijs MH Eijsvogels</dc:creator><dc:creator>哈立德·阿尔法基（Khaled Alfakih）</dc:creator><dc:creator>丽贝卡·凯瑟琳·休斯（Rebecca Kathryn Hughes）</dc:creator><dc:creator>艾哈迈德·梅尔加尼（Ahmed Merghani）</dc:creator><dc:creator>克里斯汀·K·基尔（Christine K Kissel）</dc:creator><dc:creator> Saad Fyaz</dc:creator><dc:creator> Athanasios Bakalakos</dc:creator><dc:creator> Mathew G Wilson</dc:creator><dc:creator>达米尼·迪（Damini Dey）</dc:creator><dc:creator> Gherardo Finocchiaro</dc:creator><dc:creator> Gemma Parry-Williams</dc:creator><dc:creator>卡米拉·托拉斯科（Camilla Torlasco）</dc:creator><dc:creator>迈克尔·帕帕达基斯（Michael Papadakis）</dc:creator><dc:creator>詹姆斯·C月亮</dc:creator><dc:creator>Sanjay Sharma</dc:creator><dc:date> 2025-03-10</dc:date><dc:source>循环</dc:source><dc:title>纠正：女性大师耐力运动员的冠状动脉粥样硬化患病率</dc:title><dc:identifier>PMID：40063726</dc:identifier><dc:identifier> doi：10.1161/cir.0000000001320</dc:identifier></item><item><title>校正：比较新颖的鼻内配方与口服和静脉配方的随机研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/40063725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312181054&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>循环</b>。20253月11日; 151（10）：e708</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40063725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312181054&v=2.18.0.post9+e462414">40063725</a> <a href=https://doi.org/10.1161/CIR.0000000000001317>|</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40063725</guid><pubDate> Mon, 10 Mar 2025 06:00:00 -0400</pubDate><dc:creator>安德鲁·P·安布罗斯（Andrew P Ambrosy）</dc:creator><dc:creator>丹尼尔·本辛恩（Daniel Bensimhon）</dc:creator><dc:creator> Galina Bernstein</dc:creator><dc:creator>布莱恩·科尔斯基（Brian Kolski）</dc:creator><dc:creator>乔尔·纳特尔</dc:creator><dc:creator>阿努拉达·拉拉（Anuradha Lala）</dc:creator><dc:creator> Navin K Kapur</dc:creator><dc:creator>本杰明·埃斯克（Benjamin Esque）</dc:creator><dc:creator>埃里克·阿德勒（Eric Adler）</dc:creator><dc:date> 2025-03-10</dc:date><dc:source>循环</dc:source><dc:title>校正：比较新颖的鼻内配方与口服和静脉配方的随机研究</dc:title><dc:identifier>PMID：40063725</dc:identifier><dc:identifier> doi：10.1161/cir.0000000001317</dc:identifier></item></channel></rss>